Skip to main content
Download PDF

The role of YAP/TAZ activity in cancer metabolic reprogramming

Molecular Cancer volume 17, Article number: 134 (2018) Cite this article

Abstract

In contrast to normal cells, which use the aerobic oxidation of glucose as their main energy production method, cancer cells prefer to use anaerobic glycolysis to maintain their growth and survival, even under normoxic conditions. Such tumor cell metabolic reprogramming is regulated by factors such as hypoxia and the tumor microenvironment. In addition, dysregulation of certain signaling pathways also contributes to cancer metabolic reprogramming. Among them, the Hippo signaling pathway is a highly conserved tumor suppressor pathway. The core oncosuppressive kinase cascade of Hippo pathway inhibits the nuclear transcriptional co-activators YAP and TAZ, which are the downstream effectors of Hippo pathway and oncogenic factors in many solid cancers. YAP/TAZ function as key nodes of multiple signaling pathways and play multiple regulatory roles in cancer cells. However, their roles in cancer metabolic reprograming are less clear. In the present review, we examine progress in research into the regulatory mechanisms of YAP/TAZ on glucose metabolism, fatty acid metabolism, mevalonate metabolism, and glutamine metabolism in cancer cells. Determining the roles of YAP/TAZ in tumor energy metabolism, particularly in relation to the tumor microenvironment, will provide new strategies and targets for the selective therapy of metabolism-related cancers.

Background

Metabolism is a basic characteristic of cellular activities, including material metabolism and energy metabolism. Aerobic oxidation of glucose is the main energy supply for normal cells, whereas tumor cells prefer anaerobic glycolysis to maintain their growth and survival, even in the presence of sufficient oxygen, which is known as the “Warburg effect” [1]. Cancer metabolic reprogramming not only provides ATP for tumor cells, but also provides essential macromolecules for its protein and nucleotide biosynthesis. In recent years, studies have found that tumor cell metabolic reprogramming is regulated by many different factors [2, 3], such as hypoxia and the tumor microenvironment. Under hypoxia or an inflamed microenvironment, the tumor cells significantly increase their glucose uptake and lactate production levels. In addition, the expression levels of key enzymes in the metabolic process are upregulated, such as pyruvate kinase 2 (PKM2) and glucose transporter (GLUTs). In addition, dysregulation of certain signaling pathways also contributes to cancer metabolic reprogramming [4,5,6]. However, the details of the regulatory mechanism of metabolic reprogramming in tumor cells remain unclear.

The Hippo signaling pathway is a highly conserved tumor suppressor pathway, which mainly comprises mammalian Ste20-like kinases 1/2 (MST1/2) and large tumor suppressor 1/2 (LATS1/2), yes association protein (YAP) and/or its paralog TAZ (also known as WW domain containing transcription regulator 1 (WWTR1). MST1/2 and LATS1/2 are two oncosuppressive kinases. When the Hippo pathway is activated, MST1/2 phosphorylates and activates LATS1/2, which in turn phosphorylates YAP/TAZ and inhibits YAP/TAZ activity (Fig. 1). Inactivation of this pathway is closely related to the occurrence and development of multiple tumors [7]. Most studies have found that YAP/TAZ are abnormally overexpressed in tumors and promote tumorigenesis, and considered as carcinogenic genes in many solid cancers [8,9,10], even though some evidences indicate that YAP/TAZ functions as tumor suppressors [11, 12]. Immunohistochemical staining revealed that the high expression of YAP/TAZ was mainly detected in the tumor cell nuclei [13,14,15,16]. So it indicates that the oncogenic role of YAP/TAZ mainly depends on their activity and nuclear localization. The tyrosine or serine phosphorylation of YAP/TAZ or the lysine monomethylation of YAP/TAZ may contribute to YAP/TAZ cytoplasmic retention [17,18,19]. In nucleus, the transcriptional coactivators YAP/TAZ mainly depend on multiple domains to interact with TEA domain (TEAD) transcription factors because of the lack of DNA-binding domains in YAP/TAZ [20, 21]. YAP/TAZ and TEAD form a complex in the nucleus to promote the expression and activation of downstream target genes. Recent studies have shown that Hippo pathway does not exclusively regulate YAP/TAZ phosphorylation and nuclear translation. Instead, other signaling pathways also induce YAP/TAZ activation and nuclear localization at transcriptional and post-translational levels, such as Wnt/β-catenin signaling pathway [22, 23], JNK signaling pathway [24] and Rho-GTPs signaling pathways [25], even in tumor cell energy metabolism [26, 27]. Thus, YAP/TAZ function as key nodes of multiple signaling pathways and serve as nuclear and transcriptional mediator to directly mediate target genes transcription in most cancer cells.

Fig. 1
figure 1

A simplified illustration of HIPPO signaling pathway. The Hippo signaling pathway is mainly comprised of MST1/2, Sav1, LATS1/2, Mob, YAP and/or its paralog TAZ. When the Hippo pathway is “ON”, MST1/2 phosphorylates and activates LATS1/2, which in turn phosphorylates YAP/TAZ and inhibits YAP/TAZ activity, leading to YAP/TAZ cytoplasmic retention and binding to 14–3-3 proteins or proteasomal degradation. When the Hippo signaling pathway is “OFF”, MSAT1/2 and LATS1/2 are inactivated, the transcriptional coactivators YAP/TAZ cannot be phosphorylated by LATS1/2 and freely translocate to nucleus and bind to TEAD transcription factors, promoting the expression of downstream target genes, such as CTGF and CYR61, which are involved in growth, proliferation, and survival

Full size image

The present review examines the regulatory mechanism of YAP/TAZ on glucose metabolism, fatty acid metabolism, mevalonate metabolism, and glutamine metabolism in cancer cells, and provides new concepts in our understanding of cancer metabolic reprogramming and its related molecular mechanisms.

Main text

The role of YAP/TAZ in glucose metabolism

YAP/TAZ in anaerobic glycolysis

Unlike normal cells, tumor cells rely mainly on glycolysis to provide energy and substances necessary for sustained cell proliferation, even under normoxic conditions, which is called Warburg effect [28]. Enzo et al. found that the transcriptional activity of YAP/TAZ is regulated by glucose metabolism and does not rely on the hexosamine biosynthetic pathway or protein glycosylation [29]. When YAP/TAZ are fully active, the cells increase their glucose uptake and rate of glycolysis. While inhibition of glucose metabolism or a reduction in glycolysis induces a decrease in YAP/TAZ transcriptional activity [29]. Further studies showed that the key enzyme of glycolysis, phosphofructokinase 1 (PFK1), plays an important role in this regulation (Fig. 2a) [29]. Knockout of PFK1 significantly inhibits YAP/TAZ activity. Mechanistically, in the presence of glycolysis, PFK1 binds the transcription factor TEAD1 to stabilize the binding of YAP/TAZ and TEAD1. Subsequently, PFK1-TEAD1-YAP/TAZ forms a complex in the nucleus, which is observed to promote the malignant biological behavior of breast cancer cells. This finding indicates that YAP/TAZ’s oncogenic activity could be unleashed by anaerobic glycolysis in some cancer cells undergoing metabolic reprogramming. However, two recent reports have revealed a novel post-transcriptional modification of YAP regulated by the hexosamine biosynthesis pathway (HBP) in response to metabolic nutrients (Fig. 2b) [30, 31]. The HBP is an important glucose metabolism pathway, which controls metabolic flux and O-GlcNAcylation. In high glucose conditions, O-GlcNAc transferase (OGT), which is a key enzyme of the HBP, O-GlcNAcylates YAP at different O-GlcNAc sites, such as Ser109 and Thr241, while the TAZ could not be O-GlcNAcylated. YAP O-GlcNAcylation promotes its expression, enhances its stability, prevents its phosphorylation, and activates its transcriptional activity [30, 31]. Mechanistically, Peng et al. found that YAP O-GlcNAcylation prevents LATS1-induced YAP phosphorylation by directly blocking its interaction with LATS1, the O-GlcNAcylation of YAP does not compete with phosphorylation at serine 109, it indicates that perhaps glycosylation is the main modification and functional regulator rather than phosphorylation at serine 109 [30]. In contrast, Zhang et al. revealed that O-GlcNAcylation of YAP at Thr241 antagonizes LATS1-mediated phosphorylation of YAP at Ser127, which promotes YAP transcriptional activity; Moreover, YAP is O-GlcNAcylated on its second WW domain, while TAZ has only one WW domain that might not be O-GlcNAcylated, and this may support why YAP is more important than TAZ [31]. Interestingly, both of the two reports have uncovered a positive feedback loop between YAP and cellular O-GlcNAcylation. The novel modification of YAP O-GlcNAcylation will be a potential therapeutic intervention target for cancer associated with high blood glucose levels.

Fig. 2
figure 2

A simplified illustration of YAP/TAZ and glycolysis. (a). Glycolysis upregulates the activity of PFK1 (phosphofructokinase) to promote YAP/TAZ transcriptional cooperation with TEAD factors, and form a PFK1-TEAD1-YAP/TAZ complex in cells nucleus. (b). Glycolysis activates YAP through the HBP (hexosamine biosynthesis pathway). YAP is O-GlcNAcylated by OGT (O-linked b-N-acetylglucosamine transferase). O-GlcNAcylation of YAP promotes its nuclear translocation and transcriptional activity. (c). MG (Methylglyoxal), a side-product of glycolysis, promotes YAP transcriptional cooperation with TEAD factors by reducing the binding of HSP90 and LATS1 and inhibiting LATS1 activity. (d). YAP-TEAD binds with the GLUT3 promoter to directly regulate the transcription of GLUT3 and then promotes glycolysis in tumor cells. (e). FOXC2 (forkhead box protein C2) interacts with YAP and TEAD in cells nucleus to activate YAP, and then the activation of YAP upregulates the expression of HK2 to promote cells glycolysis. (f) YAP-TEAD directly binds with the two site (GGAATT/GGAATC) in the promoter region of lncRNA BCAR4 to upregulate the expression and transcriptional activity of HK2 and PFKFB3 to promote cells glycolysis

Full size image

Methylglyoxal (MG), a side-product of glycolysis, could also activate YAP and promote the growth and metastasis in breast cancer cells (Fig. 2c) [32]. In breast cancer tissues, high level of MG is positively correlated with high expression of YAP, which is localized in cell nucleus. In addition, elevated endogenous MG levels contribute to YAP localization in the nucleus and increase YAP transcriptional activity in breast cancer cells [32]. The activation of YAP is mainly dependent on the inhibition of LATS1 kinase. Of note, LATS1 kinase is also a client of Hsp90 chaperone protein, and its expression level and activity are dependent on Hsp90 [33]. Inhibition of Hsp90 decreases LATS1 kinase stability and promotes LATS1 kinase degradation [33]. Therefore, a further mechanistic study found that MG induces post-translational glycation of Hsp90 and inactivated Hsp90, which in turn affects LATS1/2 protein stability and induces LATS1/2 kinase degradation, decreases expression of LATS1/2 then promotes YAP nuclear translocation and oncogenic activity [32]. Anaerobic glycolysis is usually considered as a downstream consequence of tumor development and can be induced by oncogenes; however, these findings suggest that glycolysis could promote tumor malignancy by regulating certain oncogenic signals, such as those induced by YAP/TAZ.

In addition to the regulation of YAP/TAZ activity by glycolysis, YAP/TAZ activation also promotes glycolysis in tumor cells. YAP-5SA (a mutant that lacks S61, S109, S127, S164, and S381 five reported LATS phosphorylation sites) is used to stably activate YAP [34], which led to a significant increase in glucose uptake and lactate production in the cell culture medium, and the YAP-5SA cell medium also shows a lower pH value [35]. Besides, active YAP promotes the transcription activity and expression of the key glycolysis enzyme GLUT3, probably via the conserved TEAD-binding site in the GLUT3 promoter (Fig. 2d). This finding indicates that YAP could promote glycolysis in tumor cells by directly regulating the transcription of GLUT3 [35]. As shown in Fig. 2e, Song et al. found that YAP is positively regulated by forkhead box protein C2 (FOXC2). Activation of YAP specifically elevates the expression of Hexokinase 2 (HK2) at both mRNA and protein level [36]. Functionally, FOXC2 acts as a bridge to interact with YAP and TEAD, and forms a FOXC2-YAP-TEAD complex, which leading to activation of HK2 and eventually promote glycolysis in nasopharyngeal carcinoma cells [36]. However, the FOXC2-YAP-TEAD complex does not bind to the promoter region of HK2, even though this complex has a positive effect on the HK2 transcriptional regulation. This mechanism remains controversial. Gao and colleges found that YAP/TEAD/p65 complex binds to the promoter region of HK2 to synergistically regulate HK2 transcription and ultimately promotes glycolysis in breast cancer cells [37]. Bringing together the two observations, it will be important to understand under different conditions, YAP/TEAD may co-operate with different transcriptional factors to regulate the target gene expression in different way. Another mechanism for the regulation of glycolysis by YAP is demonstrated recently. In breast cancer cells, long non-coding RNA breast cancer anti-estrogen resistance 4 (BCAR4) coordinates with the GLI2-dependent Hedgehog signaling to mediate YAP-induced glycolysis, and forms a YAP-BCAR4/GLI2-glycolysis axis [38]. Mechanistically, BCAR4 is a direct transcriptional target gene of YAP (Fig. 2f). The promoter region of BCAR4 has two YAP binding sites (GGAATT/GGAATC). YAP promotes BCAR4 transcription by directly binding with the two sites in the promoter region of BCAR4. Subsequently, BCAR4 activates Hedgehog effector GLI2 and forms a BCAR4/GLI2/p300 complex, which directly activates the transcription of downstream target glycolysis-related genes HK2 and PFKFB3 (6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3) through acetylation of H3K27ac histones, and ultimately promotes the glycolysis of breast cancer cells [38]. The identification of lncRNAs mediated regulation of glycolysis by YAP has improved our understanding of the regulatory mechanism between YAP and glycolysis, providing a new target for the targeted therapy of glycolysis-related diseases.

Collectively, these findings indicated that there might be a positive feedback loop between glycolysis and YAP/TAZ. On one hand, glycolysis activates YAP/TAZ transcriptional activity by promoting the expression of key glycolysis enzymes. On the other hand, YAP/TAZ exerts its oncogenic functions to increase glycolysis. It seems here that YAP/TAZ is a key metabolic hub in the regulation of glycolysis. And YAP/TAZ may also represent an ideal therapy target for cancer. However, the precise mechanism of YAP/TAZ’s involvement in glycolysis is still at an early stage, and many further outstanding questions need to be answered.

YAP/TAZ in gluconeogenesis

Gluconeogenesis is another important component of glucose metabolism, and gluconeogenesis disorder is closely related to the development of malignant tumors and insulin resistance diseases, such as diabetes and nonalcoholic fatty liver disease [39]. Gluconeogenesis is regulated by insulin and glucagon, with the involvement of many transcription factors, such as factor FoxO1 (forkhead transcription factor 1, FoxO1) [40], CREB (cAMP-response element binding protein, CREB) [41], PGC-1 (peroxisome proliferator activated receptory coactivator-1, PGC-1) [42], G-6-Pase (glucose-6-phosphatase, G-6-Pase) and PEPCK (phosphoenolpyruvate carboxykinase, PEPCK) [43, 44]. Glucagon positively regulates gluconeogenesis and stimulates net hepatic gluconeogenic flux via activation protein kinase A (PKA) in a cAMP-dependent manner, which in turn activates a variety of transcription factors, such as PGC-1 alpha and ultimately promotes the expression of gluconeogenesis genes [45].

Recently, it is observed that a high level of glucagon inhibits the expression and activity of YAP/TAZ [46, 47]. Glucagon increases cAMP levels by binding G-protein coupled receptor (GPCR). Accumulation of cAMP activates protein kinase A (PKA), which in turn inhibits Rho GTPase. This subsequently activates LATS1/2, which is a key upstream regulatory factor of YAP/TAZ [46, 47]. Activation of LATS1/2 further phosphorylates YAP at Serine 127, resulting in YAP retention in the cytoplasm and loss of transcriptional activity, ultimately leading to its degradation [46, 47]. Yue et al. showed that YAP suppresses gluconeogenesis in a PGC1α-dependent manner in primary hepatocytes [48]. Mechanistically, YAP mainly suppresses the expression of gluconeogenic genes PCK1 and G6PC in response to glucagon by inhibiting the ability of PGC1α binding to the promoters of PCK1 and G6PC [48]. Interestingly, activation of YAP only reduces the expression levels of PGC1α mRNA, but did not affect the PGC1α protein level [48]. However, the exactly mechanism on how YAP regulates PGC1α is still unclear. Yue and colleagues thought that YAP may inhibit PGC1α in an indirect way and S6 kinase may be one potential indirect mediator [48]. Therefore, further more studies are needed to demonstrate the exactly effect of YAP on PGC1α, and it will provide a new molecular mechanism for YAP to regulate glucose metabolism.

The role of YAP/TAZ in lipid metabolism

Fatty acids de novo synthesis is one of the most important metabolic hallmarks in cancer cells. Enhanced lipogenesis provides an important source of material and energy for the growth of tumors [49]. This lipogenic conversion induces high expression and activity of key enzymes involved in the fatty acid synthesis in tumor cell, such as acetyl coenzyme A carboxylase (acetyl-CoA carboxylation, ACC) and fatty acid synthase (FAS) [50,51,52,53], which in turn promotes cancer cell proliferation and survival.

Stearoyl coenzyme A desaturase 1 (SCD1) is a key enzyme involved in mono-unsaturated fatty acids synthesis, which shifts saturated fat acid synthesis to unsaturated fatty acid synthesis. Several evidences suggest that SCD1 is positively relation with a variety of malignant tumors [54,55,56]. A recent study reveals that SCD 1 promotes nuclear localization and transcriptional activity of YAP/TAZ to regulate lung cancer stemness (Fig. 3a) [57]. The regulation of YAP/TAZ by SCD1 is at least in part dependent on Wnt/β-catenin pathway activity, but not dependent on the Hippo signaling pathway. Confirming prior reports, YAP and TAZ are integral components of the β-catenin destruction complex [58]. When Wnt is on, YAP/TAZ are released from the complex, translocate to nuclear and exert their functions in transcription regulation (Fig. 3a) [58]. Noto et al. documented that SCD1 mediates the release of β-catenin and YAP/TAZ from the β-catenin destruction complex via activation Wnt ligands, which induced by increasing the synthesis of large amounts of unsaturated fatty acids (Fig. 2). This in turn promotes β-catenin and YAP/TAZ accumulation in the nucleus to promote their target genes transcription (Fig. 3a) [57].

Fig. 3
figure 3

A simplified illustration of YAP/TAZ and fatty acids. (a). SCD1 promotes the synthesis of unsaturated fatty acids. Unsaturated fatty acids activate Wnt ligand. Activation of the Wnt ligand combined with FZD4 receptor to damage the destruction complex, ultimately stabilize β-catenin and YAP/TAZ protein activity and promote β-catenin and YAP/TAZ accumulation in the nucleus to play the function role of transcription regulation. (Destruction complex: APC, Axin1, GSK3, β-TrcP). (b). Free fatty acid induces high expression of JCAD, which in turn binds to the domain of LATS2 kinase and inhibits the ability of LATS2 to phosphorylate YAP, leading to activate YAP transcription by dephosphorylating and promote YAP nuclear translocation to promote hepatoma cell proliferation. (c). Palmitate promotes YAP transcriptional activity in a F-actin-dependent manner. (d). Palmitate attaches to TEAD cysteine residues to palmitoylate TEAD, stabilizes TEAD binding to YAP/TAZ and promotes their transcriptional activity

Full size image

Besides the enzymes in the fatty acid, free fatty acids can also regulate YAP/TAZ transcriptional activity. In nonalcoholic fatty liver disease-associated hepatocellular carcinoma (NASH-HCC), the overload of free fatty acid induces a significantly high expression of junctional protein-associated with coronary artery disease (JCAD) [59]. JCAD overexpression activates YAP transcription by dephosphorylating and promoting YAP nuclear translocation (Fig. 3b). In this scenario, JCAD binds to the domain of LATS2 kinase and inhibits the ability of LATS2 to phosphorylate YAP, which in turn activating YAP to promote hepatoma cell proliferation (Fig. 3b) [59]. In concert, palmitate, a saturated free fatty acid, also promotes YAP transcriptional activity in a F-actin-dependent manner in β-cells (Fig. 3c) [60]. In addition, a recent novel and important study firstly reveals that palmitate is involved in a post-translational modification, which is called protein S-palmitoylation, via attachment to TEAD cysteine residues to indirectly regulate the transcription of YAP/TAZ (Fig. 3d) [61]. Chan et al. found that TEAD family transcription factors are autopalmitoylated at C359 in a PATs-independent manner, which is required for binding to YAP/TAZ. Palmitoylation of TEAD stabilizes its binding to YAP/TAZ and promotes their transcriptional activity (Fig. 3d) [61]. This may provide a potent treatment strategy for cancer by disrupting TEAD-YAP interaction.

Together, these observations suggest that lipid metabolism might regulate YAP/TAZ activity, yet the researches are limited and the precise mechanism remains unclear. Moreover, it would also be interesting to investigate whether YAP/TAZ could regulate lipid metabolism in cancer cells, such as lipogenesis and lipolysis.

The role of YAP/TAZ in mevalonate metabolism

The mevalonate metabolic pathway is an important pathway that mainly uses acetyl coenzyme A as the raw material to synthesize sterols and other nonsteroidal lipids. Some intermediates of mevalonate metabolism, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), are directly involved in protein prenylation, which is vital to maintain cell and lipid metabolism activities. Indeed, disruption of the mevalonate metabolic pathway leads to the occurrence of multiple tumors [62,63,64].

YAP/TAZ is a downstream transcriptional coactivating factor in the Hippo signaling pathway, and its activity is also regulated by mevalonate metabolic pathway. As shown in Fig. 3, when small-molecule inhibitors, such as statins, are used to inhibit the activity of HMG-COA reductase in the mevalonate pathway, the nuclear localization and transcriptional activity of YAP/TAZ are also inhibited [65]. In addition, GGPP plays an important role in this process. GGPP promotes YAP/TAZ nuclear localization and increases YAP/TAZ transcriptional activity via activation of Rho GTPases (Fig. 4) [65]. And activation of Rho GTPases regulated by Mevalonate also promotes YAP/TEAD to bind to hyaluronan-mediated motility receptor (HMMR; also known as RHAMM) promoter at two specific TEAD-binding sites, which in turn activates RHAMM transcription [66]. Interestingly, the regulation of YAP/TAZ by Rho GTPases is largely independent of the LATS1/2 Hippo pathway kinases, instead relying on YAP/TAZ phosphorylation [65, 66], However, the conclusion is in conflict with the previous reports that RHO induces YAP activity in a LATS1/2-depandent manner [46, 47]. Bringing together those observations, one of the reasons may be that Rho GTPases regulate YAP/TAZ activity via inhibition an unknown kinase in mevalonate metabolic pathway. However, it remains a issue to identity the relevant kinase. Another reason may be that Rho GTPases-induced YAP/TAZ activation in mevalonate pathway is distinct from YAP/TAZ activation by the cytoskeleton accumulation through inhibition of LATS kinase activity, while it is controversial whether Rho GTPases affect F-actin polymerization to regulate YAP/TAZ activity in mevalonate metabolic pathway. In addition, in a breast cancer cell line, YAP/TAZ could also be activated by SREBPs (sterol regulatory element-binding proteins), which is the main method of regulation of the mevalonate pathway [65]. Moreover, mutant p53 also promotes YAP/TAZ activity and contributes to cancer cell malignancy by sustaining SREBP expression in the mevalonate metabolic pathway (Fig. 3) [65].

Fig. 4
figure 4

A simplified illustration of YAP/TAZ and mevalonate. HMG CoA produces mevalonate through the activity of the HMG CoA reductase (HMGCR). Geranylgeranyl pyrophosphate (GGPP), the intermediate of mevalonate metabolism, activates RHO to promote YAP/TAZ transcriptional cooperation with TEAD factors in cells nucleus. Then YAP/TAZ-TEAD binds the specific sites in the RHAMM promoter to play the function role of transcription regulation. The transcription of HMG CoA reductase (HMGCR) also can be inhibited by Statins or activated by SREBP transcription factors, which can be upregualted by mutant p53. This explains why some small-molecule inhibitors such as statins could inhibit the nuclear localization and transcriptional activity of YAP/TAZ

Full size image

These in vivo and in vitro studies confirmed a new mechanism of mevalonate regulation of YAP/TAZ expression and transcriptional activity, revealing a possible process in which statins play an anticancer effect and also providing some potential targets to develop cancer treatment drugs.

The role of YAP/TAZ in glutaminolysis

The tricarboxylic acid cycle (TCA cycle) acts as the central metabolic hub and provides a majority of the energy and necessary biosynthetic precursors used by cell [67]. In order to maintain a functional TCA cycle, cancer cells often rely on elevated glutaminolysis. Therefore, glutaminolysis is another important characteristic of the energy metabolism in tumors [68]. Glutaminolysis catabolizes glutamine to yield glutamate and ammonia through the initial deamination of glutamine by glutaminase (GLS). Then glutamate is converted to α-KG, a TCA cycle intermediate, by either glutamate dehydrogenase (GDH) or transaminases [69, 70]. The major function of glutaminolysis is not only to supply α-KG to replenish the TCA cycle and generate ATP, but also provides nitrogen and anabolic carbons required for the synthesis of proteins, nucleotides and lipids macromolecule for the growth and proliferation of cancer cells [69, 70].

Recently, a connection between glutaminolysis and YAP/TAZ activity is observed. Activation of YAP/TAZ upregulates the level of glutamine, enhances the de novo nucleotides synthesis pathway, and induces the liver size to increase by promoting the expression and transcriptional activity of glutamine synthetase (GLUL) (Fig. 5a) [71]. As shown in Fig. 5b, Bertero et al. found that YAP/TAZ plays an important role in the regulation of glutamine metabolism and glycolysis in pulmonary arterial hypertension [72]. Vascular stiffness activates YAP/TAZ-dependent glutaminolysis mechanically to drive pulmonary hypertension. This activation of YAP/TAZ modulates metabolic enzymes, including glutaminase (GLS1), to coordinate glutaminolysis and glycolysis (Fig. 5b). In endothelial cells, YAP/TAZ knockdown reduces lactate production and decreases the extracellular lactate/pyruvate ratio. YAP/TAZ knockdown also blunts the effects of a stiff extracellular matrix on intracellular glutamine, glutamate, and aspartate [72]. By contrast, stable expression of YAP increases extracellular lactate and the lactate/pyruvate ratio, decreases glutamine, and increases glutamate and aspartate. Further studies reveal that the YAP/TAZ-GLS1 axis plays an important role in YAP/TAZ-dependent glutaminolysis in pulmonary vascular endothelial cells [72]. Moreover, HIV infection-induced pulmonary hypertension is also mainly caused by the YAP/TAZ-GLS1 axis [72]. The activation of the YAP/TAZ-GLS1 axis promoted glutaminolysis and caused vascular sclerosis.

Fig. 5
figure 5

A simplified illustration of YAP/TAZ and glutaminolysis. (a). Activation of YAP/TAZ upregulates the expression of glutamine by promoting the expression and transcriptional activity of glutamine synthetase (GLUL). (b). YAP/TAZ upregulates the expression of glutaminase (GLS1) to promote glutaminolysis

Full size image

Collectively, determining the regulatory role of YAP in the metabolism of glutamine will provide the impetus for the future development of targeted therapy for pulmonary hypertension and other diseases.

Conclusions

Glucose metabolism, fatty acid metabolism, mevalonate metabolism, and glutaminolysis not only provide energy for the growth of tumors, but also provide the necessary synthetic materials for the activities of tumor cells. Identifying and blocking the regulatory pathways and targets in the process of tumor metabolism will become a research hot spot in the development of tumor targeting therapy. In previous studies, YAP/TAZ has been identified as a signaling hub involved in the regulation of multiple signaling pathways in tumor cells, which promotes the initiation and development of many tumors [73,74,75,76]. Recent research on YAP/TAZ has demonstrated that the inhibition of the expression and transcriptional activity of YAP/TAZ could significantly inhibit the growth and invasion in tumor cells, and induces tumor cells apoptosis [77,78,79]. Treating tumor cells with Verteporfin, a target drugs for YAP/TAZ, significantly reversed the malignant biological behavior of the tumor cells [80,81,82,83]. Therefore, YAP/TAZ may represent ideal targets for selective tumor therapy. However, the role of YAP/TAZ in cancer metabolic reprogramming, and the specific regulatory mechanism remains unclear, thus requiring further studies. Besides, the tumor microenvironment also has a significant influence to the development of tumor cells. Hypoxia, inflammatory factors, and other microenvironment factors in the tumor microenvironment could stimulate tumor cells to undergo metabolic reprogramming. Whether YAP/TAZ have a role in in the link between tumor microenvironment and metabolic reprogramming requires further study. A deeper understanding of the role of YAP/TAZ in tumor energy metabolism will provide new strategies and targets for metabolism-related cancer therapy

Abbreviations

FOXC2:

Forkhead box protein C2

GGPP:

Geranylgeranyl pyrophosphate

GLS:

Glutaminase

GLUL:

Glutamine synthetase

GLUT3:

Glucose transporter 3

HK2:

Hexokinase 2

LATS1/2:

Large tumor suppressor 1/2

MG:

Methylglyoxal

PFK1:

Phosphofructokinase 1

PFKFB3:

6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3

PGC-1 alpha:

Peroxisome proliferator activated receptory coactivator-1

SCD1:

Stearoyl coenzyme A desaturase 1

SREBPs:

Sterol regulatory element-binding proteins

TCA cycle:

Tricarboxylic acid cycle

TEAD:

TEA domain

YAP:

Yes association protein

References

  1. Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–70.

    PubMed  CAS  Google Scholar 

  2. Semenza GL. Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype. EMBO J. 2017;36:252–9.

    Article  PubMed  CAS  Google Scholar 

  3. Liu L, Lu Y, Martinez J, et al. Proinflammatory signal suppresses proliferation and shifts macrophage metabolism from Myc-dependent to HIF1alpha-dependent. Proc Natl Acad Sci. 2016;113:1564–9.

    Article  PubMed  CAS  Google Scholar 

  4. Huang S, Chong N, Lewis NE, et al. Novel personalized pathway-based metabolomics models reveal key metabolic pathways for breast cancer diagnosis. Genome Med. 2016;8:34.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Zabala-Letona A, Arruabarrena-Aristorena A, Martin-Martin N, et al. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature. 2017;547:109–13.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496:101–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Panciera T, Azzolin L, Cordenonsi M, Piccolo S. Mechanobiology of YAP and TAZ in physiology and disease. Nat Rev Mol Cell Biol. 2017;18:758–70.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Maugeri-Sacca M, De Maria R. The hippo pathway in normal development and cancer. Pharmacol Ther. 2018;186:60–72.

    Article  PubMed  CAS  Google Scholar 

  9. Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of Cancer. Cancer Cell. 2016;29:783–803.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94:1287–312.

    Article  PubMed  CAS  Google Scholar 

  11. Cottini F, Hideshima T, Xu C, et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014;20:599–606.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Huang H, Zhang W, Pan Y, et al. YAP suppresses lung squamous cell carcinoma progression via deregulation of the DNp63-GPX2 Axis and ROS accumulation. Cancer Res. 2017;77:5769–81.

    Article  PubMed  CAS  Google Scholar 

  13. Perra A, Kowalik MA, Ghiso E, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61:1088–96.

    Article  PubMed  CAS  Google Scholar 

  14. Kim HM, Jung WH, Koo JS. Expression of yes-associated protein (YAP) in metastatic breast cancer. Int J Clin Exp Pathol. 2015;8:11248–57.

    PubMed  PubMed Central  CAS  Google Scholar 

  15. Steinhardt AA, Gayyed MF, Klein AP, et al. Expression of yes-associated protein in common solid tumors. Hum Pathol. 2008;39:1582–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Avruch J, Zhou D, Bardeesy N. YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle. 2012;11:1090–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Huang JM, Nagatomo I, Suzuki E, et al. YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene. 2013;32:2220–9.

    Article  PubMed  CAS  Google Scholar 

  18. Varelas X. The hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development. 2014;141:1614–26.

    Article  PubMed  CAS  Google Scholar 

  19. Oudhoff MJ, Freeman SA, Couzens AL, et al. Control of the hippo pathway by Set7-dependent methylation of yap. Dev Cell. 2013;26:188–94.

    Article  PubMed  CAS  Google Scholar 

  20. Hansen CG, Moroishi T, Guan KL. YAP and TAZ: a nexus for hippo signaling and beyond. Trends Cell Biol. 2015;25:499–513.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the yes proto-oncogene product. Oncogene. 1994;9:2145–52.

    PubMed  CAS  Google Scholar 

  22. Park J, Jeong S. Wnt activated beta-catenin and YAP proteins enhance the expression of non-coding RNA component of RNase MRP in colon cancer cells. Oncotarget. 2015;6:34658–68.

    PubMed  PubMed Central  Google Scholar 

  23. Liu Z, Wu H, Jiang K, et al. MAPK-mediated YAP activation controls mechanical-tension-induced pulmonary alveolar regeneration. Cell Rep. 2016;16:1810–9.

    Article  PubMed  CAS  Google Scholar 

  24. Ma X, Chen Y, Xu W, et al. Impaired hippo signaling promotes Rho1-JNK-dependent growth. Proc Natl Acad Sci. 2015;112:1065–70.

    Article  PubMed  CAS  Google Scholar 

  25. Feng X, Degese MS, Iglesias-Bartolome R, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014;25:831–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Ardestani A, Lupse B, Maedler K. Hippo signaling: key emerging pathway in cellular and whole-body metabolism. Trends Endocrinol Metab. 2018;29:492–509.

    Article  PubMed  CAS  Google Scholar 

  27. Santinon G, Pocaterra A, Dupont S. Control of YAP/TAZ activity by metabolic and nutrient-sensing pathways. Trends Cell Biol. 2016;26:289–99.

    Article  PubMed  CAS  Google Scholar 

  28. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11:325–37.

    Article  PubMed  CAS  Google Scholar 

  29. Enzo E, Santinon G, Pocaterra A, et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J. 2015;34:1349–70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Peng C, Zhu Y, Zhang W, et al. Regulation of the hippo-YAP pathway by glucose sensor O-GlcNAcylation. Mol Cell. 2017;68:591–604. e595

    Article  PubMed  CAS  Google Scholar 

  31. Zhang X, Qiao Y, Wu Q, et al. The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. Nat Commun. 2017;8:15280.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Nokin MJ, Durieux F, Peixoto P, et al. Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP-mediated tumor growth and metastasis. elife. 2016;5:e19375.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Huntoon CJ, Nye MD, Geng L, et al. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway. Cancer Res. 2010;70:8642–50.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747–61.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Wang W, Xiao ZD, Li X, et al. AMPK modulates hippo pathway activity to regulate energy homeostasis. Nat Cell Biol. 2015;17:490–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Song L, Tang H, Liao W, et al. FOXC2 positively regulates YAP signaling and promotes the glycolysis of nasopharyngeal carcinoma. Exp Cell Res. 2017;357:17–24.

    Article  PubMed  CAS  Google Scholar 

  37. Gao Y, Yang Y, Yuan F, et al. TNFalpha-YAP/p65-HK2 axis mediates breast cancer cell migration. Oncogene. 2017;6:e383.

    Article  CAS  Google Scholar 

  38. Zheng X, Han H, Liu GP, et al. LncRNA wires up hippo and hedgehog signaling to reprogramme glucose metabolism. EMBO J. 2017;36:3325–35.

    Article  PubMed  CAS  Google Scholar 

  39. Sharabi K, Lin H, Tavares CD, et al. Selective chemical inhibition of PGC-1alpha Gluconeogenic activity ameliorates type 2 diabetes. Cell. 2017;169:148–60. e115

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Wang L, Scott I, Zhu L, et al. GCN5L1 modulates cross-talk between mitochondria and cell signaling to regulate FoxO1 stability and gluconeogenesis. Nat Commun. 2017;8:523.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Erion DM, Ignatova ID, Yonemitsu S, et al. Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. Cell Metab. 2009;10:499–506.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Lee J, Salazar Hernandez MA, Auen T, et al. PGC-1alpha functions as a co-suppressor of XBP1s to regulate glucose metabolism. Mol Metab. 2018;7:119–31.

    Article  PubMed  CAS  Google Scholar 

  43. Mosseri R, Waner T, Shefi M, Shafrir E, Meyerovitch J. Gluconeogenesis in non-obese diabetic (NOD) mice: in vivo effects of vandadate treatment on hepatic glucose-6-phoshatase and phosphoenolpyruvate carboxykinase. Metabolism. 2000;49:321–5.

    Article  PubMed  CAS  Google Scholar 

  44. Wu L, Lu Y, Jiao Y, et al. Paternal psychological stress reprograms hepatic gluconeogenesis in offspring. Cell Metab. 2016;23:735–43.

    Article  PubMed  CAS  Google Scholar 

  45. Singh S, Simpson RL, Bennett RG. Relaxin activates peroxisome proliferator-activated receptor gamma (PPARgamma) through a pathway involving PPARgamma coactivator 1alpha (PGC1alpha). J Biol Chem. 2015;290:950–9.

    Article  PubMed  CAS  Google Scholar 

  46. Yu FX, Zhang Y, Park HW, et al. Protein kinase a activates the hippo pathway to modulate cell proliferation and differentiation. Genes Dev. 2013;27:1223–32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Yu FX, Zhao B, Panupinthu N, et al. Regulation of the hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150:780–91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Hu Y, Shin DJ, Pan H, et al. YAP suppresses gluconeogenic gene expression through PGC1alpha. Hepatology. 2017;66:2029–41.

    Article  PubMed  CAS  Google Scholar 

  49. Zaidi N, Lupien L, Kuemmerle NB, et al. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res. 2013;52:585–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Li W, Zhang C, Du H, et al. Withaferin a suppresses the up-regulation of acetyl-coA carboxylase 1 and skin tumor formation in a skin carcinogenesis mouse model. Mol Carcinog. 2016;55:1739–46.

    Article  PubMed  CAS  Google Scholar 

  51. Svensson RU, Parker SJ, Eichner LJ, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med. 2016;22:1108–19.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Wang MD, Wu H, Fu GB, et al. Acetyl-coenzyme a carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients. Hepatology. 2016;63:1272–86.

    Article  PubMed  CAS  Google Scholar 

  53. Li L, Pilo GM, Li X, et al. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. J Hepatol. 2016;64:333–41.

    Article  PubMed  CAS  Google Scholar 

  54. Lai KKY, Kweon SM, Chi F, et al. Stearoyl-CoA desaturase promotes liver fibrosis and tumor development in mice via a Wnt positive-signaling loop by stabilization of low-density lipoprotein-receptor-related proteins 5 and 6. Gastroenterology. 2017;152:1477–91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Angelucci C, Maulucci G, Colabianchi A, et al. Stearoyl-CoA desaturase 1 and paracrine diffusible signals have a major role in the promotion of breast cancer cell migration induced by cancer-associated fibroblasts. Br J Cancer. 2015;112:1675–86.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Huang GM, Jiang QH, Cai C, Qu M, Shen W. SCD1 negatively regulates autophagy-induced cell death in human hepatocellular carcinoma through inactivation of the AMPK signaling pathway. Cancer Lett. 2015;358:180–90.

    Article  PubMed  CAS  Google Scholar 

  57. Noto A, De Vitis C, Pisanu ME, et al. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. Oncogene. 2017;36:4573–84.

    Article  PubMed  CAS  Google Scholar 

  58. Azzolin L, Panciera T, Soligo S, et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158:157–70.

    Article  PubMed  CAS  Google Scholar 

  59. Ye J, Li TS, Xu G, et al. JCAD promotes progression of nonalcoholic steatohepatitis to liver Cancer by inhibiting LATS2 kinase activity. Cancer Res. 2017;77:5287–300.

    Article  PubMed  CAS  Google Scholar 

  60. Deng Y, Matsui Y, Pan W, Li Q, Lai ZC. Yap1 plays a protective role in suppressing free fatty acid-induced apoptosis and promoting beta-cell survival. Protein Cell. 2016;7:362–72.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Chan P, Han X, Zheng B, et al. Autopalmitoylation of TEAD proteins regulates transcriptional output of the hippo pathway. Nat Chem Biol. 2016;12:282–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Mullen PJ, Yu R, Longo J, Archer MC, Penn LZ. The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016;16:718–31.

    Article  PubMed  CAS  Google Scholar 

  63. Yeganeh B, Wiechec E, Ande SR, et al. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther. 2014;143:87–110.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Goldman AR, Bitler BG, Schug Z, et al. The primary effect on the proteome of ARID1A-mutated ovarian clear cell carcinoma is downregulation of the mevalonate pathway at the post-transcriptional level. Mol Cell Proteomics. 2016;15:3348–60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Sorrentino G, Ruggeri N, Specchia V, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014;16:357–66.

    Article  PubMed  CAS  Google Scholar 

  66. Wang Z, Wu Y, Wang H, et al. Interplay of mevalonate and hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci. 2014;111:E89–98.

    Article  PubMed  CAS  Google Scholar 

  67. Ciccarone F, Vegliante R, Di Leo L, Ciriolo MR. The TCA cycle as a bridge between oncometabolism and DNA transactions in cancer. Semin Cancer Biol. 2017;47:50–6.

    Article  PubMed  CAS  Google Scholar 

  68. Jin L, Alesi GN, Kang S. Glutaminolysis as a target for cancer therapy. Oncogene. 2016;35:3619–25.

    Article  PubMed  CAS  Google Scholar 

  69. Li T, Le A. Glutamine metabolism in Cancer. Adv Exp Med Biol. 2018;1063:13–32.

    Article  PubMed  Google Scholar 

  70. Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism in Cancer: understanding the heterogeneity. Trends Cancer. 2017;3:169–80.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Cox AG, Hwang KL, Brown KK, et al. Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol. 2016;18:886–96.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Bertero T, Oldham WM, Cottrill KA, et al. Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. J Clin Invest. 2016;126:3313–35.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Konsavage WM Jr, Kyler SL, Rennoll SA, et al. Wnt/beta-catenin signaling regulates yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem. 2012;287:11730–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Park HW, Kim YC, Yu B, et al. Alternative Wnt signaling activates YAP/TAZ. Cell. 2015;162:780–94.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Kim W, Khan SK, Gvozdenovic-Jeremic J, et al. Hippo signaling interactions with Wnt/beta-catenin and Notch signaling repress liver tumorigenesis. J Clin Invest. 2017;127:137–52.

    Article  PubMed  Google Scholar 

  76. Lee DH, Park JO, Kim TS, et al. LATS-YAP/TAZ controls lineage specification by regulating TGFbeta signaling and Hnf4alpha expression during liver development. Nat Commun. 2016;7:11961.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Lin L, Sabnis AJ, Chan E, et al. The hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015;47:250–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  78. Hiemer SE, Szymaniak AD, Varelas X. The transcriptional regulators TAZ and YAP direct transforming growth factor beta-induced tumorigenic phenotypes in breast cancer cells. J Biol Chem. 2014;289:13461–74.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Yang S, Zhang L, Purohit V, et al. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget. 2015;6:36019–31.

    PubMed  PubMed Central  Google Scholar 

  80. Hulter-Hassler D, Wein M, Schulz SD, et al. Biomechanical strain-induced modulation of proliferation coincides with an ERK1/2-independent nuclear YAP localization. Exp Cell Res. 2017;361:93–100.

    Article  PubMed  CAS  Google Scholar 

  81. Chen R, Zhu S, Fan XG, et al. High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology. 2018;67:1823–41.

    Article  PubMed  CAS  Google Scholar 

  82. Chen M, Zhong L, Yao SF, et al. Verteporfin inhibits cell proliferation and induces apoptosis in human leukemia NB4 cells without light activation. Int J Med Sci. 2017;14:1031–9.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Pan W, Wang Q, Zhang Y, et al. Verteporfin can reverse the paclitaxel resistance induced by YAP over-expression in HCT-8/T cells without Photoactivation through inhibiting YAP expression. Cell Physiol Biochem. 2016;39:481–90.

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

This study was supported by grants from the National Natural Science Foundation of China (No. 81472302).

Author information

Author notes

  1. Xiaodong Zhang and Haiying Zhao contributed equally to this work.

Authors and Affiliations

  1. Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, 4 Chongshan East Street, Shenyang, 110032, China

    Xiaodong Zhang, Haiying Zhao, Yan Li, Liang Yang, Yingbo Ma & Hangyu Li

  2. Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China

    Di Xia

Authors
  1. Xiaodong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haiying Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Di Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Liang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yingbo Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hangyu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XZ designed the review and wrote the manuscript. HZ and HL reviewed and made significant revisions to the manuscript. YL and DX draw the graph. XZ, LY and YM collected and prepared the related literature. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Hangyu Li.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, X., Zhao, H., Li, Y. et al. The role of YAP/TAZ activity in cancer metabolic reprogramming. Mol Cancer 17, 134 (2018). https://doi.org/10.1186/s12943-018-0882-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12943-018-0882-1

Keywords

Molecular Cancer

ISSN: 1476-4598